Product
GRT-R902
3 clinical trials
4 indications
Indication
Colorectal CancerIndication
Lung CancerIndication
Gastroesophageal adenocarcinomaIndication
Bladder CancerClinical trial
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2027-03-01
Clinical trial
A Randomized, Open-Label, Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer With Minimal Residual Disease Following Surgical Resection and Standard Adjuvant ChemotherapyStatus: Terminated, Estimated PCD: 2022-09-01
Clinical trial
An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-11-10